Aberdeen Group
IOVA icon

Aberdeen Group’s Iovance Biotherapeutics IOVA Stock Holding History

Aberdeen Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-155,000
Closed -$544K – 959
2026
Q1 		$544K Sell
155,000
-604,522
-80% -$1.93M ﹤0.01% 874
2025
Q4 		$2.07M Buy
759,522
+152,312
+25% +$352K ﹤0.01% 775
2025
Q3 		$1.32M Buy
607,210
+90,921
+18% +$215K ﹤0.01% 817
2025
Q2 		$888K Buy
516,289
+384,489
+292% +$957K ﹤0.01% 837
2025
Q1 		$439K Hold
131,800
– – ﹤0.01% 879
2024
Q4 		$975K Hold
131,800
– – ﹤0.01% 826
2024
Q3 		$1.24M Hold
131,800
– – ﹤0.01% 797
2024
Q2 		$1.06M Buy
+131,800
New +$1.41M ﹤0.01% 818

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Aberdeen Group's IOVA Position: Q2 2026 in Review

Aberdeen Group sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 155,000 shares — an estimated $544K sold.

Aberdeen Group first reported a position in IOVA in Q2 2024 and held it in 8 quarters. The position peaked at $2.07M in Q4 2025. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Aberdeen Group reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Aberdeen Group sold 155,000 Iovance Biotherapeutics shares in Q2 2026, an estimated $544K.
  • Aberdeen Group first reported a position in Iovance Biotherapeutics in Q2 2024 and held it in 8 quarters.
  • Aberdeen Group's Iovance Biotherapeutics position peaked at $2.07M in Q4 2025.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.